Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference

On December 1, 2022 Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, reported that the Company will present at the Antibody Engineering and Therapeutics Conference, the Antibody Society’s Annual Meeting, to be held in-person in San Diego, CA from December 4-8, 2022 (Press release, Kineta, DEC 1, 2022, View Source;utm_medium=rss&utm_campaign=kineta-to-participate-in-jmp-securities-hematology-and-oncology-summit [SID1234624652]). Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, will give an oral presentation on KVA12123 (formerly referred to as KVA12.1). KVA12123 is the Company’s VISTA blocking immunotherapy that is expected to initiate Phase 1 clinical trials in patients with advanced solid tumors in the fourth quarter of 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Title: KVA12123 (formerly referred to as KVA12.1), a VISTA Blocking Immunotherapy

Presenter: Thierry Guillaudeux, Ph.D.

Date / Time: December 7, 2022, at 8:45 A.M. Pacific Time

Session Type: Oral Presentation

A copy of the presentation will be available on the Kineta website under Publications after the conference on December 7, 2022: View Source